Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight

Recently published Drug-Resistant Epilepsy Market Insights report includes a comprehensive understanding of current treatment ...

Pershing Square Holdings H2 2025 Letter To Shareholders

Pershing Square Holdings reported a 20.9% NAV return in 2025, outperforming the S&P 500. Read the full analysis for detailed ...

DelveInsight Business Research, LLP: Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight

DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness ...
News-Medical.Net

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...